Trial Profile
Safety and Tolerability of Single Ascending Doses (SAD) of a Novel Engineered Cationic Peptide PLG0206 in Healthy Subjects
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs PLG 0206 (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; First in man
- Sponsors Peptilogics
- 27 Nov 2018 New trial record
- 26 Nov 2018 Recruitment completion is expected on 02 Jan 2019.